MARLBOROUGH, Mass., June 29, 2011 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight™ Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announced today that its technology was featured in a live case and scientific abstract presented at the European Heart Rhythm Association (EHRA) EUROPACE 2011 congress on June 28 in Madrid, Spain.
The case, "Atrial fibrillation ablation using laser balloon technology," demonstrated successful isolation of all pulmonary veins in a single procedure with HeartLight EAS. Presenters Vivek Y. Reddy, MD, of Mount Sinai School of Medicine, New York, USA and Petr Neuzil, MD, of Na Homolce Hospital, Prague, Czech Republic, performed the ablation on a 69-year-old male with paroxysmal AF at Na Homolce Hospital.
"The advantages offered by HeartLight EAS made it a very favorable system to address the patient's atrial fibrillation," said Dr. Reddy. "The system offers direct visualization of the heart tissue, which helped ensure contiguity of the ablation lesions. Clinical data indicates that because of this, HeartLight EAS offers an improved ability to achieve durable, reproducible PV isolation."
Additionally, an abstract presentation, "Is pure visually guided pulmonary vein isolation feasible using an endoscopic ablation system?," examined the use of HeartLight EAS in 35 patients with drug-refractory atrial fibrillation. In a single procedure, HeartLight EAS with the aid of a supplemental spiral catheter achieved an acute pulmonary vein (PV) isolation rate of 98%. Among the 18 patients completing six months follow up, 78% were in stable sinus rhythm without antiarrhythmic drugs.
"The compliant balloon catheter enables optimal visualization and tissue contact," said Julian Chun, MD, of Cardioangiologisches Centrum Bethanien, Frankfurt, Germany and one of the presenting physicians. "Physicians can use the technology to isolate all veins, regardless of individual
|SOURCE CardioFocus, Inc.|
Copyright©2010 PR Newswire.
All rights reserved